NTLA

Beam Therapeutics Overview: Beam Therapeutics is developing innovative gene therapies using its proprietary base-editing technology, with candidates like BEAM-101 for sickle cell disease showing promising early results. However, the company faces challenges due to its lack of approved products and reliance on partnerships for growth.

Intellia Therapeutics Overview: Intellia Therapeutics focuses on in vivo gene therapies and is advancing late-stage candidates like lonvo-z for hereditary angioedema. The company recently faced setbacks with its nex-z candidate due to a clinical hold from the FDA, raising safety concerns.

Investment Comparison: While both companies are in the gene editing space, Beam Therapeutics is considered a safer investment despite its higher valuation, as it has a broader pipeline and less immediate risk compared to Intellia, which is dealing with regulatory issues.

Market Performance: Year-to-date, Beam's stock has gained 1%, while Intellia's has dropped 27%. Both companies hold a Zacks Rank of #3 (Hold), indicating uncertainty in choosing between them, but Beam's fundamentals and recent stock performance suggest potential for growth.

Reasons for Short Selling: Traders short stocks to either bet on a decline in value or to profit from potential short squeezes, where rising prices force short sellers to buy back shares, creating a feedback loop of increasing demand.

Characteristics of Heavily Shorted Stocks: Stocks become heavily shorted when experienced traders believe they are overvalued, indicating serious risks, while retail traders may see high short interest as an opportunity for quick gains.

Top Heavily Shorted Stocks: As of November 26, 2025, the most shorted stocks include The Wendy's Co. (WEN) at 55.36% short interest, followed by Cambium Networks Corp. (CMBM) and Lucid Group, Inc. (LCID).

Risks and Volatility: While short squeezes can lead to significant gains, they come with high risks and volatility, necessitating careful monitoring and due diligence by traders.